1. Progress in antisense technology;Crooke;Annu. Rev. Med.,2004
2. Fomivirsen approved for CMV retinitis;Roehr;J. Int. Assoc. Physicians AIDS Care,1998
3. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha;Sewell;J. Pharmacol. Exp. Ther.,2002
4. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer;Chi;J. Natl. Cancer Inst.,2005
5. Topigen reports positive therapeutic results from initial phase II trial studying inhaled TPI-ASM8 in patients with mild-to-moderate asthma. Phase II data validates TPI-ASM8 clinical targets and efficacy of multi-targeted antisense in the respiratory tract. Company press release, July 18, 2006